Clinical Trials Logo
  1. Home
  2. Recurrent Skin Cancer
  3. NCT01791894

Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma — ATO  

Recurrent Skin Cancer Clinical Trial

Official title:
An Open-label, Biomarker Study of Arsenic Trioxide for the Treatment of Patients With Basal Cell Carcinoma

Clinical Trial Summary

This pilot clinical trial studies arsenic trioxide in treating patients with basal cell carcinoma. Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stop them from dividing

Clinical Trial Description

PRIMARY OBJECTIVES:

I. To determine whether administration of arsenic trioxide (ATO) to patients with basal cell carcinoma is associated with a reduction in Gli messenger ribonucleic acid (mRNA) and protein levels in tumor biopsy samples, when compared to baseline levels.

SECONDARY OBJECTIVES:

I. To determine whether there is evidence of tumor size reduction of ATO against basal cell carcinoma in humans.

OUTLINE:

Patients receive arsenic trioxide intravenously (IV) over 2 hours on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01791894
Study type Interventional
Source Stanford University
Contact
Status Completed
Phase Phase 1/Phase 2
Start date April 2013
Completion date November 2015
View Details
See also
  Status Clinical Trial Phase
Completed NCT00563290 - Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia Phase 2
Terminated NCT01823679 - Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin Phase 2
Completed NCT01292668 - Photodynamic Therapy Using Methyl-5-Aminolevulinate Hydrochloride Cream in Determining Pain Threshold in Patients With Skin Cancer Phase 1
Completed NCT00126555 - Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer Phase 2
Completed NCT00089180 - T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant Phase 2
Completed NCT01631331 - Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC) Early Phase 1
Completed NCT02324608 - Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer N/A
Terminated NCT02303041 - Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma Phase 2
Withdrawn NCT01465815 - Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN) Phase 1/Phase 2
Withdrawn NCT02507076 - Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma N/A